このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (NEXT-CAT)

2026年9月25日 更新者:Eun Kyoung Kim、Samsung Medical Center

Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis

This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.

調査の概要

状態

まだ募集していません

詳細な説明

Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality in patients with active cancer. Patients with CAT are at increased risk of both recurrent venous thromboembolism and bleeding during anticoagulant treatment, making the balance between efficacy and safety particularly important when selecting an anticoagulant.

Non-vitamin K antagonist oral anticoagulants have become established treatment options for CAT. Edoxaban and apixaban are both factor Xa inhibitors with demonstrated efficacy and safety in patients with CAT. However, they have been evaluated separately against low-molecular-weight heparin, and direct randomized comparisons between edoxaban and apixaban are lacking. The two agents also differ in dosing frequency, dose-reduction strategies, pharmacokinetic characteristics, and renal elimination. Whether these differences translate into differences in overall clinical outcomes in patients with CAT remains uncertain.

NEXT-CAT is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to directly compare edoxaban-based treatment with apixaban-based treatment in patients with active cancer and objectively confirmed venous thromboembolism. A total of 2,300 participants will be randomized in a 1:1 ratio, with randomization stratified by participating center and the presence of gastrointestinal cancer at baseline.

The primary hypothesis is that edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to the incidence of net adverse clinical events (NACE). The primary endpoint is a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Participants will be followed at 1, 3, 6, 9, 12, and 18 months after randomization and annually thereafter, with follow-up continuing until 1 year after enrollment of the last participant.

Clinical events corresponding to the primary and secondary endpoints will be evaluated by an independent Clinical Event Adjudication Committee blinded to treatment allocation.

研究の種類

介入

入学 (推定)

2300

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Busan、韓国
        • Dong-A University Hospital
        • コンタクト:
          • Sung-Hyun Kim
        • 主任研究者:
          • Sung-Hyun Kim, MD, PhD
      • Goyang、韓国
        • Inje University Ilsan Paik Hospital
        • コンタクト:
          • Min Sun Kim
        • 主任研究者:
          • Min Sun Kim
      • Gwangmyeong、韓国
        • Chung-Ang University Gwangmyeong Hospital
        • コンタクト:
          • Eun Jeong Cho
        • 主任研究者:
          • Eun Jeong Cho
      • Hwasun、韓国
        • Chonnam National University Hwasun Hospital
        • コンタクト:
          • Hyukjin Park
        • 主任研究者:
          • Hyukjin Park
      • Jeonju、韓国
        • Chonbuk National University Hospital
        • コンタクト:
          • Ho-Young Yhim
        • 主任研究者:
          • Ho-Young Yhim, MD, PhD
      • Seoul、韓国
        • Kangbuk Samsung Hospital
        • コンタクト:
          • Jiwon Kim
        • 主任研究者:
          • Jiwon Kim
      • Seoul、韓国
        • Korea University Anam Hospital
        • コンタクト:
          • So Ree Kim
        • 主任研究者:
          • So Ree Kim
      • Seoul、韓国
        • Samsung Medical Center
        • 副調査官:
          • Se-Hoon Lee, MD, PhD
        • 副調査官:
          • Taek Kyu Park, MD, PhD
        • コンタクト:
        • 主任研究者:
          • Eun Kyoung Kim, MD, PhD
        • 副調査官:
          • David Hong, MD, PhD
      • Seoul、韓国
        • Seoul National University Hospital
        • コンタクト:
          • Sang-Hoon Na, MD, PhD
        • 主任研究者:
          • Sang-Hoon Na, MD, PhD
      • Seoul、韓国
        • Konkuk University Medical Center
        • コンタクト:
          • Ji-Won Hwang
        • 主任研究者:
          • Ji-Won Hwang
      • Seoul、韓国
        • Seoul St. Mary's Hospital
        • コンタクト:
          • Mi-Hyang Jung
        • 主任研究者:
          • Mi-Hyang Jung, MD, PhD
    • Gyeonggi-do
      • Goyang-si、Gyeonggi-do、韓国
        • National Cancer Center
        • コンタクト:
          • Mi-Hyang Kwak
        • 主任研究者:
          • Mi-Hyang Kwak

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age ≥19 years.

  2. Objectively confirmed symptomatic or incidentally detected venous thromboembolism (VTE), including:

    • Proximal deep vein thrombosis (DVT)
    • Pulmonary embolism (PE)
    • Both DVT and PE.
  3. Any type of active cancer, defined by at least one of the following:

    • Cancer diagnosed within the previous 6 months
    • Locally advanced or metastatic cancer
    • Receipt of cancer-directed therapy (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy, or cancer surgery) within the previous 6 months
    • Cancer not in complete remission at the time of enrollment
    • Ongoing cancer treatment or residual cancer.
  4. Ability to understand the risks, benefits, and treatment alternatives of the study and to voluntarily provide written informed consent.

Exclusion Criteria:

  1. Known hypersensitivity or contraindication to either study drug (edoxaban or apixaban).
  2. Severe renal impairment (creatinine clearance <15 mL/min) or dialysis.
  3. Active major bleeding.
  4. An indication requiring alternative anticoagulation, such as a mechanical heart valve or moderate-to-severe mitral stenosis.
  5. Antiphospholipid syndrome.
  6. Life expectancy <6 months due to cancer progression or comorbid conditions, or anticipated poor treatment adherence, as determined by the investigator.
  7. Pregnancy or breastfeeding.
  8. Moderate or severe hepatic impairment classified as Child-Pugh class B or C.
  9. Thrombocytopenia with a platelet count <50,000/mm³.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Edoxaban-based Treatment

Participants randomized to this arm will receive oral edoxaban once daily. The standard dose is 60 mg once daily, with dose reduction according to the protocol based on renal function, body weight, concomitant P-glycoprotein inhibitors, and other prespecified clinical factors.

Edoxaban is administered orally once daily. The standard dose is 60 mg once daily. The dose is reduced to 30 mg once daily in participants with a creatinine clearance of 15-50 mL/min, body weight ≤60 kg, or concomitant use of specified P-glycoprotein inhibitors. In participants aged ≥80 years who are considered at high risk of bleeding and meet the prespecified criteria, further dose reduction to 15 mg once daily may be considered.

アクティブコンパレータ:Apixaban-based Treatment

Participants randomized to this arm will receive oral apixaban twice daily. The standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily according to the prespecified dose-reduction criteria in the protocol.

Apixaban is administered orally at a standard dose of 5 mg twice daily. The dose is reduced to 2.5 mg twice daily in participants who meet the prespecified dose-reduction criteria, including those who meet at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, or those with severe renal impairment with a creatinine clearance of 15-29 mL/min.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Net Adverse Clinical Events (NACE)
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.

From randomization until 1 year after enrollment of the last participant

二次結果の測定

結果測定
メジャーの説明
時間枠
Recurrent Venous Thromboembolism or Venous Thromboembolism-related Death
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of recurrent venous thromboembolism or venous thromboembolism-related death.

From randomization until 1 year after enrollment of the last participant
Recurrent Venous Thromboembolism
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of objectively confirmed recurrent venous thromboembolism, including recurrent deep vein thrombosis or recurrent pulmonary embolism.

From randomization until 1 year after enrollment of the last participant
Venous Thromboembolism-related Death
時間枠:From randomization until 1 year after enrollment of the last participant

Death resulting from objectively confirmed fatal pulmonary embolism, recurrent venous thromboembolism directly leading to death, or unexplained death for which no alternative cause is identified and which is adjudicated as venous thromboembolism-related by the Clinical Event Adjudication Committee.

From randomization until 1 year after enrollment of the last participant
Major Bleeding According to International Society on Thrombosis and Haemostasis Criteria
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of major bleeding according to International Society on Thrombosis and Haemostasis criteria, including fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a decrease in hemoglobin of at least 2 g/dL, or bleeding requiring transfusion of at least 2 units of whole blood or packed red blood cells.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Non-major Bleeding
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant non-major bleeding, defined as clinically overt bleeding that does not meet the criteria for major bleeding but leads to hospitalization or an increased level of care, medical or surgical treatment, or a change in antithrombotic therapy.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Bleeding
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
Broad Net Adverse Clinical Events
時間枠:From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a broad net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, major bleeding, or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
All-cause Mortality
時間枠:From randomization until 1 year after enrollment of the last participant

Death due to any cause occurring during the study follow-up period.

From randomization until 1 year after enrollment of the last participant
Permanent Discontinuation Due to Adverse Events
時間枠:From randomization until 1 year after enrollment of the last participant

Permanent discontinuation of the assigned study drug due to any adverse event during follow-up.

From randomization until 1 year after enrollment of the last participant

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2029年12月31日

研究の完了 (推定)

2030年12月31日

試験登録日

最初に提出

2026年9月25日

QC基準を満たした最初の提出物

2026年9月25日

最初の投稿 (実際)

2026年10月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data that underlie the results reported in the main publication may be shared with qualified researchers upon reasonable request.

IPD 共有時間枠

Beginning after publication of the main study results; no predetermined end date.

IPD 共有アクセス基準

Data may be made available to qualified researchers upon reasonable request for scientifically appropriate research purposes. Requests will be reviewed by the principal investigator and the study steering committee based on the scientific merit and appropriateness of the proposed research and data-use plan. Data sharing will be conducted in accordance with applicable regulations and participant privacy requirements.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する